Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

New Alzheimer's Definition to Aid in Trial Selection

October 11, 2010 8:18 am | News | Comments

A new lexicon that revises and unifies the definition of Alzheimer's disease to include recent developments in the field, in which biomarkers are the key to diagnosis, has been proposed by an international group of Alzheimer's disease experts.


Researchers Develop Improved Delivery for Bowel Disease

October 11, 2010 8:15 am | News | Comments

Delivering short strands of RNA into cells has become a popular research area because of its potential therapeutic applications, but until now, how to deliver them into targeted cells in a living organism has been an obstacle.


Allon Completes Davunetide Trial

October 11, 2010 8:04 am | News | Comments

Allon Therapeutics Inc.'s lead candidate, davunetide, met its primary trial endpoint of safety and tolerability in patients with progressive supranuclear palsy and other types of frontotemporal dementia.


FDA Rejects Jazz Drug

October 11, 2010 7:59 am | News | Comments

Federal regulators want additional clinical studies of a fibromyalgia drug candidate from Jazz Pharmaceuticals. New clinical trials could take years to complete, delaying approval for the drug JZP-6 and significantly increase expenses for Jazz.


Meridia Withdrawn in US and Canada

October 11, 2010 7:55 am | by Matthew Perrone | News | Comments

Abbott Laboratories said it will withdraw its diet pill Meridia in the U.S. and Canada, after coming under pressure from health regulators who say the drug increases the risk of heart attack and stroke in patients with a history of heart disease.


Sanofi Laying Off 1,700 in US

October 11, 2010 7:53 am | by Linda A. Johnson | News | Comments

Sanofi-Aventis SA, the world's fourth-biggest drugmaker, said it is eliminating 1,700 jobs in its U.S. pharmaceutical business in a restructuring triggered by growing generic competition and other factors.


Mining for Trial Participants

October 11, 2010 7:42 am | by Ted Agres, Contributing Editor | Articles | Comments

Fifteen academic medical centers, research institutes, and major pharmaceutical companies are collaborating to enhance the speed and quality of clinical trials by harnessing patient data emerging from the coming widespread adoption of electronic health records.


Laying the IT Foundations

October 11, 2010 7:36 am | by David Chiang, Chief Executive Officer, Sage-N Research, Milpitas, Calif. | Articles | Comments

The development of effective data analysis and storage solutions for high-throughput mass spectrometry.


Expanding Nanotechnology

October 11, 2010 7:28 am | by Mike May, Contributing Editor | Articles | Comments

Nano-size approaches fan out across pharma.


High-Throughput Proof

October 11, 2010 7:21 am | by Victoria Echeverria BellBrook Labs, Madison, Wis.; Andrew Goulter, Wayne Bowen, Paul Wylie, TTP LabTech Ltd., Royston, U.K. | Articles | Comments

Validating a high-throughput angiogenesis assay using laser scanning cytometry.


Dual Purpose

October 11, 2010 6:58 am | by James Netterwald, PhD, MT (ASCP), Contributing Editor | Articles | Comments

New antibody-based therapies and emerging research tools bolster this multi-purpose molecule.


Precast Mini Gels

October 8, 2010 7:52 am | Product Releases | Comments

ProteaGel Precast Mini Gels are a great alternative to pouring your own SDS-PAGE gels due to the time savings and high resolution provided by a precast gel.


Biological Sequencing Software

October 8, 2010 7:46 am | Product Releases | Comments

Accelrys, Inc. announced the release of Accelrys Draw 4.0. Accelrys Draw enables scientists to draw, edit, compare, and explore complex biological sequences along with chemical structures and reactions, improving intellectual property management.


MorphoSys Buys Sloning for €19M

October 8, 2010 7:30 am | News | Comments

MorphoSys AG announced the acquisition of the private German company Sloning BioTechnology GmbH, a biotechnology company developing new methods of synthetic biology.


Cepheid And Novartis Working Together on Blood Test

October 8, 2010 7:27 am | News | Comments

Cepheid announced a collaboration with Novartis to commercialize a test for the BCR-ABL gene transcript in peripheral blood specimens from patients diagnosed with Philadelphia chromosome-positive chronic myelogenous leukemia.



You may login with either your assigned username or your e-mail address.
The password field is case sensitive.